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Alzheimer’s disease (AD) is a severe chronic neurodegenerative disorder of the brain characterised by progressive impairment in
memory and cognition. In the past years an intense research has aimed at dissecting the molecular events of AD. However, there
is not an exhaustive knowledge about AD pathogenesis and a limited number of therapeutic options are available to treat this
neurodegenerative disease. Consequently, considering the heterogeneity of AD, therapeutic agents acting on multiple levels of the
pathologyareneeded.Recentﬁndingssuggestthatphytochemicalscompoundswithneuroprotectivefeaturesmaybeanimportant
resources in the discovery of drug candidates against AD. In this paper we will describe some polyphenols and we will discuss their
potentialroleasneuroprotectiveagents.Speciﬁcally,curcumin,catechins,andresveratrolbeyondtheirantioxidantactivityarealso
involved in antiamyloidogenic and anti-inﬂammatory mechanisms. We will focus on speciﬁc molecular targets of these selected
phytochemical compounds highlighting the correlations between their neuroprotective functions and their potential therapeutic
value in AD.
1.Introduction
Alzheimer’s disease (AD) is a decisive challenge to the health
care system throughout the world and it is the result of a
long chain of events leading to neuronal dysfunction and
impairment in memory and cognitive abilities. The two core
pathological hallmarks of AD are senile plaques (SPs) and
neuroﬁbrillary tangles (NFTs). To date, there are several
experimentalreportssupportingtheideathatoxidativestress
is associated with the early development of AD [1]. In addi-
tion, recent studies suggest that inﬂammatory processes may
signiﬁcantly contribute to the progression of AD [2]. Specif-
ically, the aggregation of beta-amyloid (Aβ) oligomers acti-
vate diﬀerent signaling pathways through interactions with
neuronal membranes causing oxidative stress and inﬂamma-
tory responses. Furthermore, Aβ plaques can interfere with
the neurotransmitter acetylcholine (ACh) aﬀecting synaptic
transmission and initiate inﬂammatory mechanisms that
produce reactive oxygen species (ROS) [3]. Another cause
that leads to cell death in AD is the hyperphosphorylation of
tau protein that normally stabilizes the microtubules. When
tau presents a high level of phosphorylation it becomes dys-
functional;thereforethemicrotubulecollapseandtheresult-
ing NFTs block neurotransmitters and neuronal signaling.
However, AD is a multifaceted neurodegenerative disorder
andtheresearchersdonotknowenoughaboutthebiologyof
AD to identify the right targets. Since we do not have a com-
prehensive picture of the disease, the therapeutic landscape
for AD is wide open. Moreover, it is necessary to emphasize
that the new therapies must be based on molecular target
and biomarkers. For instance, a good biomarker would be
useful in the clinic but it could also help to design drugs to
slow the decline [4]. Currently, a successful treatment is
lacking and the medications available do not delay or modify2 Oxidative Medicine and Cellular Longevity
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Figure 1: Chemical structures of Curcumin. Curcumin belongs to the class of curcuminoids and the presence of double bonds increases its
potency and reactivity. The phytochemical curcumin undergoes keto-enol tautomerism.
the disease progression even though several potential drug
targets have been identiﬁed. In this scenario, plant-derived
compounds with multiple target mechanisms might play a
roleindrugdevelopmentanddiscovery.Anumberofstudies
demonstrated potential health-promoting properties in the
use of natural products as therapeutics for AD [5, 6]. More-
over several epidemiological reports have documented the
inﬂuence of dietary habits on the incidence of neurodegen-
erative disorders. In particular, it was suggested a signiﬁcant
positive correlation between the consumption of polypheno-
lic phytochemical-rich foods and the prevention of certain
neurological diseases, including AD [5]. Although these
ﬁndings need to be interpreted with caution and it is still
early to deﬁne such compounds as neuroprotective, several
observationsraisethepossibilitythattheymighthaveprotec-
tive eﬀects and might be able to slow the progression of AD.
Among the numerous natural products of emerging interest
with anti-AD properties, we will focus on some polyphenolic
phytochemicals and on their potential role as antiamy-
loidogenic, anti-oxidative, and anti-inﬂammatory activities,
highlighting speciﬁc molecular targets that might play a
crucial function in the neuroprotection from AD.
2. Some CandidatesPolyphenolic
Phytochemicals for the Neuroprotection
from AD
Polyphenolsareaclassofplant-derivedsubstancescharacter-
ized by the presence of more than one phenol structuralunit.
Intheplants,theyareinvolvedinthedefencefrompathogens
attacks or stress induced by chemical and physical damage.
These compounds exert their protective action also in the
animals by modulating several intracellular processes that
preserve the neurons. In the following sections, we include
some polyphenolic compounds, such as curcumin, (−)-
epigallocatechin-3-gallate (EGCG) and resveratrol, that have
received attention as alternative candidates for AD therapy.
2.1. Curcumin. Curcumin (1,7-bis [4-hydroxy-3-methox-
yphenyl]-1,6-heptadiene-3,5-dione) or diferuloylmethane is
extracted from the rhizome of Curcuma longa [7]. The struc-
ture is often shown in the keto form, but recent NMR studies
demonstrated that curcumin exists in solution as keto-
enol tautomers [8]( Figure 1). Numerous pieces of evidence
suggest that curcumin may be a promising therapy for AD
because it has diﬀerent neuroprotective activities, including
antioxidant [9], anti-inﬂammatory [10] and antiamyloido-
genic properties [11]. Curcumin has been demonstrated to
have a strong antioxidant neuroprotective eﬀects, scavenging
ROS [12] and neutralizing nitric-oxide-(NO-) based free
radicals [13]. However, one of the issues of curcumin as a
therapeutic agent in the treatment of AD is its poor water
solubility [14], which is one reason for its low bioavailability
following oral administration or through parenteral route
[15]. The poor bioavailability is one of the causes of its
failure in randomized control trials for AD. The structural
features of curcumin that can contribute to the antioxidant
activity are the phenolic and the methoxy group on the
phenyl ring and the 1,3-diketone system. Moreover, the
antioxidantactivityofcurcuminincreaseswhenthephenolic
group with a methoxy group is at the ortho position [16, 17].
Theorthomethoxygroupcanformanintramolecularhydro-
gen bond with the phenolic hydrogen, making the H-atom
abstraction from the orthomethoxyphenols surprisingly easy
[18]. The H abstraction from these groups is responsible for
the remarkable antioxidant activity of curcumin. Moreover,
t h er e a c t i o n so fc u r c u m i nw i t hf r e er a d i c a l sp r o d u c eap h e -
noxylradicalsandacarbon-centeredradicalatthemethylene
CH2 group [19]( Figure 2). Additional experimental reports
supporting the antioxidant property of curcumin were
provided by Lim and coworkers using an AD transgenic
mouse model which demonstrated that curcumin reduces
brain levels of oxidized proteins containing carbonyl groups
[20]. In vivo, the antioxidant activity of curcumin may be
mediated through antioxidant enzymes such as superoxide
dismutase (SOD), catalase (CAT), and glutathione perox-
idase (GSH-Px). Curcumin has been shown to serve as
a Michael acceptor, reacting with glutathione (GSH) and
thioredoxin [21]. Depletion in cellular GSH levels is an
important measure of oxidative stress, which is implicated
in the pathogenesis of AD. A study on postmortem brain
of AD patients has revealed decreased levels of GSH in
some area of the brain [22]. Also, the GSH levels were low
in the red blood cells of male AD subjects, conﬁrming an
associationbetweenGSHandAD[23].Noteworthy,thereare
some studies reporting the restorative eﬀect of curcumin onOxidative Medicine and Cellular Longevity 3
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Figure 2: Reaction mechanism of curcumin with free radicals. The reactions produce phenoxyl radicals and carbon-centered radical at the
methylene CH2 group.
GSH depletion. For instance, it was demonstrated that
curcumin is able to replenish the intracellular GSH pool by
changing the nuclear content and/or activation of spe-
ciﬁc transcription factors such as 12-tetradecanoate 13-
acetate (TPA-) responsive elements (TRE) and electro-
philic response element (EpRE) [24]. Moreover, curcumin
enhances the antioxidant enzyme activities of SOD and CAT
in the striatum and mid-brain of 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-(MPTP-)injectedmice[25].Takinginto
account that in vivo evidence showed that peroxynitrite
induces Alzheimer-like tau hyperphosphorylation, nitration,
and accumulation [26], it was reported that curcumin medi-
ates the direct detoxiﬁcation of reactive nitrogen species such
as peroxynitrite, thus exerting an antioxidant activity [27].
Furthermore, the pieces of evidence to support a role of
oxidative stress in AD brain with elevated levels of lipid
peroxidation increasing [28]. Oxidative damage of lipids
generates toxic aldehydes such as 4-hydroxy-2-nonenal (4-
HNE) and malondialdehyde (MDA) leading to cell death.
Important cytopathologies in AD brain include a decreased
activity of all electron transport chain complexes [29]. In
particular, complex IV decreases in AD, which causes release
of oxidants during mitochondrial electron transport [30].
It was reported that excessive Aβ binds to regulatory heme,
triggering functional heme deﬁciency and causing the key
cytopathologies of AD. Additionally, Aβ-heme complex is
a peroxidase and curcumin signiﬁcantly inhibits the per-
oxidase activity of Aβ-heme [31]. The Tg2576 mouse
model of AD exhibits impaired mitochondria metabolic
activity in the spinal cord and curcumin partially suppressed
the mitochondrial impairment reversing motor function
deﬁcits [32]. Interestingly, curcumin treatment abrogates
lipid peroxidation protecting mitochondria from oxidative
damage and apoptosis in cortical neurons [33]. Moreover,
curcumin has been also shown in PC12 cells to provide
protection against the deleterious eﬀects of 4-HNE on
mitochondrial redox metabolism, cytochrome c release, and
DNA fragmentation [34]. The increased level of oxidative
stress in AD is reﬂected by the increased brain content of
iron (Fe2+)a n dc o p p e r( C u 2+) both capable of stimulating
free radical formation. In addition to its properties of
quencher, curcumin showed to be able to bind Cu2+ and
Fe2+ ions [35]. Since these redox-active metals ions can
intensify Aβ aggregation, curcumin may prevent this aspect
of AD pathogenesis. Other reports suggested that curcumin
regulates Fe2+ metabolism by modulation of Fe2+ regulatory
proteins; therefore it may act as an iron chelator [36].
Signiﬁcantly, in vivo studies reported that another divalent
metal cation such as zinc (Zn2+) is highly enriched in Aβ
plaques [37, 38] but its role in the amyloid landscape is
still poorly understood and under investigation. However,
even though curcumin more readily binds to the redox-
active metals such as Cu2+ and Fe2+, it was also reported
relatively weak aﬃnity for the redox-inactive metal Zn2+
which might exert a small protective eﬀe c ta g a i n s tA β by
inducing metal chelation [35]. Recently, a systematic review4 Oxidative Medicine and Cellular Longevity
highlighted the importance of inﬂammatory processes in
the pathogenesis of AD [39]. AD secretes increasing levels of
multiple inﬂammatory mediators, and considering the anti-
inﬂammatory characteristic of curcumin, it was reported
that this polyphenol reduced the level of interleukin-1β
(IL-1β), a proinﬂammatory cytokine that appears elevated
in the brains of AD-like mice [20]. Findings on the anti-
inﬂammatory eﬀects of curcumin were also provided by Jin
et al. demonstrating that this natural phenol reduces the
release of proinﬂammatory cytokines, such as IL-1β,I L - 6 ,
and tumor necrosis factor-alpha (TNF-α)[ 40]. Indeed, cur-
cumin abolished the proliferative eﬀects of IL-6 because it
inhibits the phosphorylation of signal transducer and acti-
vator of transcription 3 (STAT3) [41]. In a similar manner,
curcumin downregulates the transcription factor activator
protein 1 (AP1) through direct interaction with its DNA
binding motif [42] and inducing the inhibition of IL-1α
and TNF-α [43]. Several experimental lines suggest that the
anti-inﬂammatory capacity of curcumin is associated to the
reduction of the activity of nuclear transcription factors NF-
kβ signaling pathway [44]. NF-kβ enhances the transcription
of proinﬂammatory genes, such as inducible nitric oxide
synthase (iNOS). In inﬂammatory cells, iNOS catalyzes
the synthesis of NO, which can react with superoxide to
form peroxynitrite which damages proteins and DNA.
Curcumin has been found to inhibit NF-kβ-dependent
gene transcription and the induction of iNOS in animal
studies and macrophages cell culture [45, 46]. Probably, the
inhibition of AP1 and NF-kβ occurs through the chro-
matin remodelling activity of curcumin that is able to
modulate some histone deacetylases (HDAC) activity [47].
Moreover, curcumin attenuates the inﬂammatory responses
through the inhibition of lipoxygenase and cyclooxygenase-
2 (COX-2) enzymes, which are responsible of the synthesis
of proinﬂammatory prostaglandins and leukotrienes [48].
Interestingly, the anti-inﬂammatory and neuroprotective
eﬀects of curcumin against dopamine induced neuronal
death have also been demonstrated by Lee and coworkers
which established that the inﬂammatory conditions induced
by microglial activation are the main target for curcumin
[49]. Noteworthy, curcumin exhibits protective eﬀects on
neuronal cells by inhibiting the aggregation of Aβ into
oligomers and clearance eﬀect on the exsting Aβ [50]. A very
interesting in vivo approach with multiphoton microscopy
showed the ability of curcumin to cross the blood-brain bar-
rier(BBB)anddisruptamyloidplaques[51].Additionally,in
aged female rats with induced AD-like phenotype, curcumin
prevented Aβ-induced spatial memory deﬁcits in the Morris
water maze assay, postsynaptic density loss, and reduced Aβ
deposits [52]. As mentioned above, curcumin is able to clear
amyloid plaques through several mechanisms and an addi-
tional activity that may be relevant is the induction of heat
shock proteins (HSPs) molecular chaperones that are able
to block protein aggregate formation [53]. However, even
though several experimental research showed that curcumin
exhibit high aﬃnity binding to Aβ aggregates, one study
reported the relationship between the tautomeric structures
of curcumin, its derivatives, and their Aβ-binding activities.
In particular, the results achieved by UV-visible spectroscopy
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Figure 3: Chemical structure of (−)-Epigallocatechin-3-gallate.
EGCG contains three heterocyclic rings, A, B, and C, and the free
radical scavenging property of EGCG is attributed to the presence
of trihydroxyl group on the B ring and the gallate moiety at the
3  position in the C ring.
revealedthattheenolizationiscrucialforthebindingandthe
enol forms of the curcumin derivatives are the predominant
binding species for Aβ aggregates [54]. These important
ﬁndings may represent a novel strategy for the design of
therapeutic drugs or diagnostic tools in AD. Recently, Long-
v i d a ,ac u r c u m i nf o r m u l a t i o n ,h a sb e e ne v a l u a t e di na
Phase II Alzheimer’s clinical trial (NCT01001637). Taking
into account the low bioavailability of curcumin and its
inability to reach required blood concentrations necessary
to aﬀect disease markers, Longvida is a solid lipid curcumin
particle (SLCP) preparation and it was reported relatively
higherbioavailabilityofSLCPcomparedtogenericcurcumin
extract. Furthermore, this formulation is able to maintain
plasma concentration of curcumin above the threshold
required for the biological activity [55].
2.2. (−)-Epigallocatechin-3-gallate (EGCG). EGCG
([(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl) chro-
man-3-yl] 3,4,5-trihydroxybenzoate) (Figure 3) is the
most common phenolic constituent of green tea with
several pharmacological activities associated with diﬀerent
beneﬁcial health eﬀects. It was well documented a powerful
free radical scavenging activity for this catechin which might
be attributed to the presence of the trihydroxyl group on
the B ring and the gallate moiety esteriﬁed at the 3  position
in the C ring [56]. Furthermore, it was demonstrated in a
human model of BBB the pharmacokinetics of catechin and
epicatechin that could cross the BBB in a time-dependent
manner [57]. EGCG penetrates the BBB at a low rate and the
bioavailability after oral administration was approximately
5% [58]. It should be noted that high doses of EGCG were
associated to death in rat hippocampal neuron through
the mitochondrial-dependent pathway [59] and also that at
highconcentrationsithasaprooxidant/proapoptoticactivity
[60]. However, considering that Aβ can induce mitochon-
drial dysfunction, it was also demonstrated that EGCG
treatment is able to restore mitochondrial respiratory rates,
altered mitochondrial membrane potential, and ROS
production or ATP levels [61]. An increasing number of
publications reports the ability of EGCG to modulate
multiple biological pathways. Indeed, it has been shown toOxidative Medicine and Cellular Longevity 5
regulate several biomedically important targets and to exert
neuroprotection in many ways. In addition to the anti-
inﬂammatory properties, EGCG exerts protection by
regulating diﬀerent survival genes and controlling numerous
antioxidant protective enzymes [62]. Advanced glycation
end-products are involved in the neuronal injury associated
with several neurodegenerative disorders. EGCG increased
SOD activity and protected against glycation end products-
induced neurotoxicity by decreasing ROS and MDA [63].
Another demonstration that EGCG may have preventive
and/or therapeutic potential in AD has been shown in BV2
microglia cell lines and in rat hippocampus where EGCG
treatment increased cellular GSH pool through elevated
mRNA expression of gamma-glutamylcysteine ligase (GCL)
which provides neuroprotection from Aβ cytotoxicity [64].
On D-galactose-treated aged mice, EGCG treatment led to
the increment of SOD and GSH-Px activities decreasing
MDA contents in the hippocampus [65]. Moreover, it is
interesting that the attenuation of monoamine oxidase
(MAO) activity may provide protection against oxidative
neurodegeneration. EGCG supplementation in adult rat
brains was able to exert an inhibitory action on MAO-B
preventing physiological peroxidation [66]. As mentioned
above for the curcumin, EGCG acts as an antioxidant
protecting rat hippocampal neurons against NO stress-
induced neuronal damage by deoxidizing peroxynitrate/
peroxynitrite produced after ischemia [67]. Recently, it was
established the pivotal role of iron in neurodegeneration
and recent studies examined the eﬀect of EGCG in the
Fe2+ chelating process demonstrating neurorestorative
activity and Fe2+-chelating properties [62]. Considering that
the binding of EGCG to Fe2+ is essential for its antioxidant
activity, among 12 phenolic compounds tested EGCG is
the most potent inhibitor of the Fe2+-mediated DNA break
[68] .Ac o n s i d e r a b l en u m b e ro fe v i d e n c eh a v ee l u c i d a t e d
the importance of several cell signaling pathways in the
neuroprotectiveactionofEGCG.Severalstudiesindicatethat
EGCG aﬀects mitogen-activated protein kinases (MAPK),
NF-kβ and protein kinase C (PKC) pathways [69]. In
support of these observations, EGCG has been shown
to mediate the phosphorylation of PKC promoting the
survival of human neuroblastoma SH-SY5Y cells from Aβ
and 6-hydroxydopamine (6-OHDA)-induced neurotoxicity
[70]. Other evidence on the pharmacological actions of
EGCG and its potential therapeutic applications to various
neurodegenerative diseases such as AD were provided by
Kim et al. EGCG in human astrocytoma U373MG cells
suppressed NF-kβ activation and phosphorylation of MAPK
p38 and the c-Jun N-terminal kinase [71]. Additional
investigations have indicated that EGCG prevented the
expression of COX-2, iNOS, the release of NO, and
proinﬂammatory cytokines from astrocytes and microglia
by inhibiting MAPK signaling cascades [72]. Moreover,
administration of EGCG prevented lipopolysaccharide-
(LPS-) mediated apoptotic cell death through the reduction
of the levels of Aβ and inhibited the elevation of the
expression of iNOS and COX-2 [73]. Considerably, EGCG
is able to modulate enzymes that are involved in amyloid
precursor protein (APP) processing and reduces the
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Figure 4: Chemical structure of resveratrol. The 4 -OH in resver-
atrol provides its chemical and biological features.The transfer of
protons or hydrogen atoms to reactive species appears to be crucial
to its antioxidant mechanism.
formation of β-amyloid plaques in cell culture and in vivo
[74]. Intraperitoneal administration of EGCG attenuated
brain Aβ neuropathology and improved cognitive function
in a transgenic AD mouse model [75]. In particular, EGCG
inhibits the ﬁbrillogenesis of Aβ through the binding to
the natively unfolded polypeptides and preventing their
conversion into toxic aggregates intermediates [76].
Considering the inhibitory function of EGCG on the Aβ
generation, it was previously shown that catechins are able
to inhibit formation, extension, and destabilization of
β-amyloid ﬁbrils [77] and EGCG mediates the block of
β-secretase activity [78]. Additionally, Obregon and
coworkers studied the involvement of three candidate
α-secretase enzymes in EGCG-induced nonamyloidogenic
APP metabolism. The results showed that a-disintegrin and
metalloprotease-10 (ADAM-10) is necessary for EGCG-
mediated α-secretase cleavage activity in APP processing;
thus potential stimulators of ADAM-10 such as EGCG could
prevent the amyloidosis associated to AD [79]. A further
study revealed that through the inhibition of extracellular
signal-regulated protein kinase (ERK) and NF-kβ pathways,
the treatment with EGCG in mutant AD mice improved
memory function enhancing the α-secretase function and
reducing the activities of β-and γ-secretases with
subsequentlydecreaseinthelevelsofAβ[80].Ithasalsobeen
reported synergistic eﬀects between EGCG and ﬁsh oil on
the decrease in AD-like pathology in Tg2576 mice [81]a n d
in a recent study Li et al. showed that the administration
of this or similar compound may improve spatial memory
preventing the decrease in the proteins involved in the
synaptic function and structure [82]. EGCG has a wide
array of biological eﬀects and it is a promising compound
which has been proven eﬃcacious in AD animal models.
Lastly, EGCG has an excellent tolerability and has resulted in
ongoing Phase II/III clinical trials (NCT00951834).
2.3. Resveratrol. Resveratrol (5-[(E)-2-(4-hydroxyphenyl)
ethenyl] benzene-1,3-diol) is a phytoalexin polyphenolic
compound (Figure 4) found in grapes and other plants. In
recent years many studies have reported interesting insights
about the antiaging eﬀects of resveratrol in diﬀerent organ-
isms including nematodes, yeast, rat, and mice. Indeed,
resveratrol modulates various systems that protect cells6 Oxidative Medicine and Cellular Longevity
providing neuroprotective features both in vitro and in vivo
in models of AD. Many studies reported that the central
nervous system (CNS) is one of the resveratrol’s targets. This
compund is able to pass the BBB [83] but the bioavailability
is low because it is quickly metabolized into glucuronide
and sulfate conjugates. Several lines of evidence indicate
a strong antioxidant functions together with other phar-
macological activities, therapeutic and protective properties
[84]. Regarding the radical-scavenging activity, structural
studies and theoretical calculations demonstrate that in the
antioxidant reaction of resveratrol the hydroxyl group at
the 4 -position is much easier to subject to oxidation than
other hydroxyl groups [85]. Intraperitoneally administra-
tion of resveratrol exerts neuroprotective properties up-
regulating several endogenous antioxidant enzymes such as
SOD and CAT [86]. Prolonged administration of resveratrol
improves colchicine-induced cognitive impairment, reduces
MDA and nitrite levels, and restores depleted GSH [87].
However, it is important to emphasize that resveratrol can
exhibit prooxidant activities in the presence of transition
m e t a li o n ss u c ha sC u 2+, leading to oxidative breakage of
cellular DNA [88] .As u b s t a n t i a la m o u n to fr e s e a r c hh a s
attributed to this phytocompound the capacity to increase
the activity of SIRT1 that are NAD+-dependent class III
histone deacetylases [89]. Consequently, resveratrol appears
to possess the ability to activate sirtuins and to mimic caloric
restriction [84]. In a mouse model of AD, a calorie-restricted
diet attenuates AD pathogenesis through an increase in
SIRT1 activity [90]. Additionally, it was reported that calor-
ic restriction reduces Aβ deposition and Aβ-associated
neuropathology in diﬀerent animal models [91, 92]. In
a meaningful way Kim et al. showed in transgenic AD mouse
model that resveratrol reduced neurodegeneration through
a decrease in the acetylation of known SIRT1 substrates, for
example, peroxisome-proliferator-activated receptor gamma
coactivatoralpha(PGC-1α)andp53[93].SIRT1activatedby
resveratrolprotectscellsagainstAβ-inducedROSproduction
andreducesamyloidneuropathology inthebrainsofTg2576
mice [94]. Taking into account that resveratrol can be
considered a neuroprotective compound in the context of
AD,itispossibletospeculatethattheabilitytocounteractAβ
toxicity can occur through its antioxidant properties but also
through SIRT1 activation. Deﬁnitely, resveratrol is reported
to possess antiamyloidogenic activity in several studies, for
example, the treatment with this stilbenoid resulted in the
inhibition of β-amyloid peptide polymerization even though
the antiamyloidogenic mechanism is still unknown [95]. As
illustrated by Marambaud and colleagues, resveratrol pro-
motes clearance of intracellular Aβ by activating its pro-
teasomal degradation [96]. Moreover, SIRT1 overexpression
reduces Aβ pathology in APP-expressing neuronal cultures
by delaying Aβ synthesis [96, 97]. A recent work oﬀers
interesting insights into the eﬀects of resveratrol on the
polymerization, cell toxicity, and destabilization of Aβ ﬁbril
suggesting that resveratrol disrupts Aβ hydrogen binds thus
preventing ﬁbril formation, destabilizing preformed ﬁbril
without aﬀecting oligomerization [98]. Furthermore, in a
diﬀerent study it was noticed that the protective eﬀects
of resveratrol on β-amyloid protein-induced toxicity in rat
hippocampal cells are related to activation of PKC [99]. It
is noteworthy to mention that resveratrol might be involved
in the attenuation of neuroinﬂammatory responses because
it is able to reduce the concentration of 8-iso-prostaglandin
F2α, an indicator of free radical generation [100]. It has
also been shown that resveratrol inhibits COX-1 but in
contrast it does not aﬀect the expression of COX-2 [100].
Since NF-kβ signaling activation plays an important role
in the neurodegeneration, another link between AD and
neuroprotective activity of resveratrol is its ability to reduce
the expression of genes modulated by NF-kβ,s u c ha si N O S ,
prostaglandin E2 (PGE2), as well as cathepsin and NO
[101]. One of the main ﬁndings reported by Lu et al. was
that resveratrol attenuates LPS-stimulated NF-κBa c t i v a t i o n
in murine primary microglia and astrocytes and suggests
that the inﬂammatory responses induced by LPS could be
limited by resveratrol, with diﬀerent potencies [102]. Studies
performed in ischemia-reperfusion models have demon-
strated that resveratrol inhibits peroxisome proliferator-
activated receptors alpha (PPARα)[ 103]a n dr e d u c e sN F -
kβ p65 expression [104]. Moreover, resveratrol was found
to activate AMPK and reduce cerebral Aβ levels and depo-
sition in the mice cortex [105]. Using electron microscopy
and biochemical methods, it was reported that resveratrol
prevents the abnormal expression of peroxiredoxins but also
mitochondrial structural abnormalities in a mouse model of
primary AD and Aβ-incubated mouse neuroblastoma cells
[106].
Currently, resveratrol is under Phase III clinical trials
(NCT00678431) studies to determine the eﬀects in mild-to
moderate AD in combination with glucose and malate.
3. Activation of the Keap1/Nrf2 System
for Neuroprotection by Curcumin,EGCG,
andResveratrol
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a con-
served master regulator of cellular antioxidant responses.
As mentioned above, multiple pieces of evidence support
the role of oxidative stress in the pathogenesis of AD [1].
Therefore, Nrf2 appears to be a good candidate to pro-
vide neuroprotection in AD. Nrf2 belongs to the CnC
(Cap’n’Collar) family leucine zipper transcrption factors and
regulates the expression of genes encoding antioxidant and
detoxifyingproteinssuchasglutathioneS-transferase(GST),
glutathione synthetase (GSS), heme oxygenase 1 (HO-1) and
NAD(P)H:quinone oxidoreductase [12]. Under basal con-
ditions, Nrf2 is sequestered in the cytoplasm by Keap1
(Kelch-like ECH-associating protein 1), which facilatites its
polyubiquitylation and proteasome-mediated degradation.
Keap1 functions as a sensor of stress signals and the exposure
to electrophiles, oxidants, or xenobiotics disrupts Keap1-
Nrf2 complex, thus stabilizing Nrf2 and allowing it to
accumulate in the nucleus. Nrf2 activates the trascrption of
its target genes via antioxidant response elements (AREs) in
their promoter regions binding as a heterodimer with the
members of Maf and Jun family [12]. To date, only few
pieces of evidence show that the activation of Nrf2 and of
its cytoprotective genes by curcumin, EGCG, and resveratrolOxidative Medicine and Cellular Longevity 7
treatments is suﬃcient to protect against AD. However,
Chen et al. reported that resveratrol is able to increase the
expression of HO-1 and glutathione protecting PC12 cells
from oxidative stress via activation of Nrf2-ARE signaling
pathway [107] which indirectly suggests a potential role in
AD treatment. Similarly, using primary neuronal cultures,
resveratrol was able to signiﬁcantly induce HO-1, presum-
ably through the activation of Nrf2 [108]. Yet, curcumin
induces HO-1 increasing tolerance of the brain to stresses
andprovidinganimportantantidegenerativefunctioninAD
pathogenesis [109]. Moreover, curcumin activates GST [110]
restoring GSH content in the brain and improving cognitive
deﬁcits [111]. Recently, consistent with the potential role
of Nrf2 as therapeutic target in AD, it was observed that
the incubation of Nrf2+/+ astrocytes with curcumin led to a
signiﬁcantinductionofphaseIIenzymes[112].Additionally,
data from our laboratory have shown the ability of low
dose EGCG to stimulate HO-1 expression in rat cultured
neurons. In this study, Nrf2 was found to be upregulated
in neurons exposed to nontoxic concentrations of EGCG,
suggesting that this compound may induce HO-1 via the
activation of Nrf2 [113]. These results are in agreement
with another study, where it was showed the ability of
epicatechins to protect neurons and reduce brain infarct
size of mice. Moreover, neuroprotection was abolished in
neurons derived from knockout mice for HO-1 and Nrf2
[114]. In conclusion, Nrf2 is an attractive target for the
discovery of natural neuroprotective agents against AD and
these few examples can already be considered promising.
4. Cocktail of Drugs for Neuroprotection
Given the complexity and the multiple etiological nature
of AD and other neurodegenerative disorders, a successful
treatment may require a cocktail of compounds. Indeed,
therapeutic approaches that are based on single biological
mechanisms or targets may be inadequate. Also considering
that certain regions of the brain respond diﬀerently to the
treatments or are more aﬀected than others, a cocktail of
drugs may be more eﬀective. Despite this, almost no studies
have been done with a combination of neuroprotective
drugs,especiallywithcurcuminorresveratrol.However,new
drug candidates for AD should be able to act on multiple
brain targets for the treatment of cognition impairment,
motor dysfunction, depression, and neurodegeneration. It is
evident that the neurodegenerative disorders require multi-
ple-target therapies to counteract the heterogeneous patho-
logical aspects of the disease. For instance, a multifunctional
neuroprotective-neurorescue compound might be endowed
withproperties thatinclude (1)antiﬁbrilsformationandﬁb-
rilsdestabilizingaction;(2)promotionofneuriteoutgrowth;
(3) a direct neutralization of free-radicals-induced oxidative
stress; (4) maintenance of mitochondrial integrity; (5) mod-
ulation of the activity of antioxidant detoxifying enzymes;
(6) reduction in AβPP/α synuclein translation; (7) activation
of transcription factors; (8) attenuation of reactive free-iron
pool. To date, it is plausible that some of these actions
may result only from a combination therapy of more com-
pounds.Inhumanneuroblastomacells,EGCGcausesarapid
decrease in proapoptotic factors whereas R-apomorphine
upregulates anti-apoptotic proteins [115]b u tb o t hc o m -
pounds are also iron chelators; therefore they complement
each other and induce a synergistic neuroprotective action.
However, it should be underlined that plant polyphenols are
recognized as multifunctional agents for neuroprotection,
providing polypharmacological activities in addition to their
established radical scavenging action. Therefore, multidrug
medication therapy can be eﬀective because single-target
approachmaybeinadequateforheterogeneousdisordersbut
at the same time one compound with two or more mecha-
nisms of action, targeted at diﬀerent pathological aspects of
the disease may oﬀer a good therapeutic eﬃcacy.
5. Conclusions
The pathogenesis of AD is multilateral and its poly-
etiological origin requires new drug candidates capable
to operate on multiple brain targets for the treatment of
cognition and motor dysfunction, depression, and neurode-
generation. In this paper we present some phytochemical
entities able to act on speciﬁc targets implicated in the
pathogenesis of AD. The neuroprotective activity of
curcumin, EGCG, and resveratrol has been demonstrated in
vitro and in various models of neurodegenerative diseases
in vivo. Consequently, it is reasonable to propose these
substances as promising resources in the development of
new medications for AD aimed to prevent and/or to treat
this neurodegenerative disorder. Additionally, even though
there are limits for their widespread use, such protective
molecules appear to be innocuous, tolerate, inexpensive,
and available. However, their eﬃcacy and utility in the
clinical pharmaceutical is still an open question because an
exhaustive amount of experimental evidence is still missing.
In addition, although the neuroprotective eﬀects of the
phytocompounds above described are attractive for their
multiple biological activities, more long-term studies should
be performed at least to determine their eﬀects in slowing
the development of AD. Furthermore, it is still unclear which
is the ideal concentration for the compound to be in the
active forms and exert its beneﬁcial eﬀects. In conclusion,
polyphenols have revealed to be in the ﬁeld of neurosciences
promising neuroprotective compounds with great potential
that continues to expand.
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